Reversal of CPT-11 resistance of lung cancer cells by adenovirus- mediated gene transfer of the human carboxylesterase cDNA

Cancer Research

Volumn 58, Issue 19, 1998, Pages 4368-4374

  Kojima, Akira ^a   Hackett, Neil R ^a   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; COMPLEMENTARY DNA; IRINOTECAN;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHEMOSENSITIVITY; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; LUNG CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ADENOCARCINOMA; ADENOVIRUSES, HUMAN; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CELL DIVISION; CELL SURVIVAL; CLONE CELLS; DNA TOPOISOMERASES, TYPE I; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032188839     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Takimoto, C. H., and Arbuck, S. G. The camptothecins. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biothcrapy, pp. 463-484. Philadelphia: Lippincott-Raven Publishers, 1996.
2. Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T., and Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against mutine tumors. Cancer Res., 47: 5944-5947, 1987.
3. Ohno, R., Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, H., Ichimaru, M., Sakai, Y., Oguro, M., Ho, Y., Morishima, R., Yokomaku, S., and Ota, K. An early Phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol., 8: 1907-1912, 1990.
4. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S., and Taguchi, T., for the CPT-11 Lung Cancer Study Group. A Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10: 16-20, 1992.
5. Masuda, N., Fukuoka, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Negoro, S., Nishioka, M., Nakagawa, K., and Takada, M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10: 1225-1229, 1992.
6. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T., and Ogawa, N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J. Clin. Oncol., 11: 909-913, 1993.
7. Kaneda, N., Nagata, H., Furuta, T., and Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
8. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51: 4187-4191, 1991.
9. Andoh, T., Ishii, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, Y., and Okada, K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. USA, 84: 5565-5569, 1987.
10. Gupta, R. S., Gupta, R., Eng, B., Lock, R. B., Ross, W. E., Hertzberg, R. P., Caranfa, M. J., and Johnson, R. K. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res., 48: 6404-6410, 1988.
11. Tan, K. B., Mattern, M. R., Eng, W. K., McCabe, F. L., and Johnson, R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer Inst., 81: 1732-1735, 1989.
12. Eng, W. K., McCabe, F. L., Tan, K. B., Mattern, M. R., Hofmann, G. A., Woessner, R. D., Hertzberg, R. P., and Johnson, R. K. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol. Pharmacol., 38: 471-480, 1990.
13. Kanzawa, F., Sugimoto, Y., Minato, K., Kasahara, K., Bungo, M., Nakagawa, K., Fujiwara, Y., Liu, L. F., and Saijo, N. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res., 50: 5919-5924, 1990.
14. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Isoe, T., and Tsuruo, T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50: 6925-6930, 1990.
15. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Liu, L. F., and Tsuruo, T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res., 50: 7962-7965, 1990.
16. Chang, J. Y., Dethlefsen, L. A., Barley, L. R., Zhou, B. S., and Cheng, Y. C. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem. Pharmacol., 43: 2443-2452, 1992.
17. Tanizawa, A., and Pommier, Y. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res., 52: 1848-1854, 1992.
18. Woessner, R. D., Eng, W. K., Hofmann, G. A., Rienian, D. J., McCabe, F. L., Hertzberg, R. P., Mattern, M. R., Tan, K. B., and Johnson, R. K. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol. Res., 4: 481-488, 1992.
19. Matsumoto, Y., Fujiwara, T., Honjo, Y., Sasaoka, N., Tsuchida, T., and Nagao, S. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11. J. Surg. Oncol., 53: 97-103, 1993.
20. Madelaine, I., Prost, S., Naudin, A., Riou, G., Lavelle, F., and Riou, J. F. Sequential modifications of topoisomerase I activity in a camptolhecin-resistant cell line established by progressive adaptation. Biochem. Pharmacol., 45: 339-348, 1993.
21. Kijima, T., Kubota, N., and Nishio, K. Establishment of a CPT-11-resistant human ovarian cancer cell line. Anticancer Res., 14: 799-803, 1994.
22. Kapoor, R., Slade, D. L., Fujimori, A., Pommier, Y., and Harker, W. G. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res., 7: 83-95, 1995.
23. Matsumoto, Y., Fujiwara, T., and Nagao, S. Determinants of drug response in CPT-11-resistant glioma cell lines. J. Neuro-Oncol., 23: 1-8, 1995.
24. Nagai, S., Yamauchi, M., Andoh, T., Nishizawa, M., Satta, T., Kodera, Y., Kondou, K., Akiyama, S., Ito, K., and Takagi, H. Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin). J. Surg. Oncol., 59: 116-124, 1995.
25. Beidler, D. R., Chang, J. Y., Zhou, B. S., and Cheng, Y. C. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res., 56: 345-353, 1996.
26. Fujimori, A., Gupta, M., Hoki, Y., and Pommier, Y. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair. Mol. Pharmacol., 50: 1472-1478, 1996.
27. Kojima, A., Hackett, N. R., Ohwada, A., and Crystal, R. G. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J. Clin. Investig., 101: 1789-1796, 1998.
28. Hersh, J., Crystal, R. G., and Bewig, B. Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Gene Ther., 2: 124-131, 1995.
29. Rosenfeld, M. A., Yoshimura, K., Trapnell, B. C., Yoneyama, K., Rosenthal, E. R., Dalemans, W., Fukayama, M., Bargon, J., Stier, L. E., Stratford-Perricaudet, L., Perricaudet, M., Guggino, W. B., Pavirani, A., Jecocq, J. P., and Crystal, R. G. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell, 68: 143-155, 1992.
30. Thomas, P. S. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc. Natl. Acad. Sci. USA, 77: 5201-5205, 1980.
31. Mertz, L. M., and Rashtchian, A. Nucleotide imbalance and polymerase chain reaction: effects on DNA amplification and synthesis of high specific activity radio-labeled DNA probes. Anal. Biochem., 221: 160-165, 1994.
32. Krisch, K. Reaction of a microsomal esterase from hog-liver with diethyl rhonitrophenyl phosphate. Biochim. Biophys. Acta, 122: 265-280, 1966.
33. Barilero, I., Gandia, D., Armand, J. P., Mathieu-Boue, A., Re, M., Gouyette, A., and Chabot, G.G. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. J. Chromatogr., 575: 275-280, 1992.
34. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
35. Liu, L. F., and Miller, K. G. Eukaryotic DNA topoisomerases. Two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc. Natl. Acad. Sci. USA, 78: 3487-3491, 1981.
36. Deffie, A. M., Batra, J. K., and Goldenberg, G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res., 49: 58-62, 1989.
37. Hirschowitz, E. A., Ohwada, A., Pascal, W. R., Russi, T. J., and Crystal, R. G. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum. Gene Ther., 6: 1055-1063, 1995.
38. Masuda, N., Fukuoka, M., Takada, M., Kusunoki, Y., Negoro, S., Matsui, K., Kudoh, S., Takifuji, N., Nakagawa, K., and Kishimoto, S. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J. Clin. Oncol., 10: 1775-1780, 1992.
39. de Forni, M., Bugat, R., Chabot, G. G., Culine, S., Extra, J. M., Gouyette, A., Madelaine, I., Marty, M. E., and Mathieu-Boue, A. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res., 54: 4347-4354, 1994.
40. Abigerges, D., Chabot, G. G., Armand, J. P., Herait, P., Gouyette, A., and Gandia, D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol., 13: 210-221, 1995.
41. Oshita, F., Noda, K., Nishiwaki, Y., Fujita, A., Kurita, Y., Nakabayashi, T., Tobise, K., Abe, S., Suzuki, S., Hayashi, I., Kawakami, Y., Matsuda, T., Tsuchiya, S., Takahashi, S., Tamura, T., and Saijo, N. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J. Clin. Oncol., 15: 304-309, 1997.
42. Kudoh, S., Fujiwara, Y., Takada, Y., Yamamoto, H., Kinos, A., Furuse, K., and Fukuoka, M. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J. Clin. Oncol., 16: 1068-1074, 1998.
43. Shao, R. G., Cao, C. X., Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res., 57: 4029-4035, 1997.
44. Senter, P. D., Marquardt, H., Thomas, B. A., Hammock, B. D., Frank, I. S., and Svensson, H. P. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Cancer Res., 56: 1471-1474, 1996.
45. Danks, M. K., Morton, C. L., Pawlik, C. A., and Potter, P. M. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res., 58: 20-22, 1998.
46. Goldwasser, F., Pourquier, P., Gutierrez-Toro, Y., Misset, J. L., Pommier, Y., and Levi, F. Effect of melatonin upon CPT-11-induced DNA damages, cell cycle response, and cytotoxicity. Proc. Am. Assoc. Cancer Res., 39: 526, 1998.
47. Aogi, K., Nishiyama, M., Kim, R., Hirabayashi, N., Toge, T., Mizutani, A., Okada, K., Sumiyoshi, H., Fujiwara, Y., Yamakido, M., Kusano, T., and Andoh, T. Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential. Int. J. Cancer. 72: 295-300, 1997.
48. Moolten, F. L. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther., 1: 279-287, 1994.
49. Chen, S. H., Shine, H. D., Goodman, J. C., Grossman, R. G., and Woo, S. L. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA. 91: 3054-3057, 1994.
50. Mackillop, W. J., Ward, G. K., and O'Sullivan, B. The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. Br. J. Cancer, 54: 661-667, 1986.
51. Raby, B., Pater, J., and Mackillop, W. J. Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J. Clin. Oncol., 13: 1904-1911, 1995.
52. Brundage, M. D., Davidson, J. R., and Mackillop, W. J. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J. Clin. Oncol., 15: 330-340, 1997.
53. Choi, N. C., Carey, R. W., Daly, W., Mathisen, D., Wain, J., Wright, C., Lynch, T., Grossbard, M., and Grillo, H. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage III a non-small-cell lung cancer. J. Clin. Oncol., 15: 712-722, 1997.
54. Schaake-Koning, C., van den Bogaen, W., Dalesio, O., Festen, J., Hoogenhout, J., van Houtte, P., Kirkpatrick, A., Koolen, M., Maat, B., Nijs, A., Renaud, A., Rodrigus, P., Schuster-Uitterhoeve, L., Sculier, J., Zandwick, N. V., and Bartelink, H. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med., 326: 524-530, 1992.